{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:20:18Z","timestamp":1788942018969,"version":"build-2803163510"},"reference-count":42,"publisher":"Galenos Yayinevi","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["dir"],"published-print":{"date-parts":[[2024,1,1]]},"DOI":"10.4274\/dir.2022.221818","type":"journal-article","created":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T14:32:16Z","timestamp":1679322736000},"page":"55-64","source":"Crossref","is-referenced-by-count":8,"title":["Pre-emptive transjugular intrahepatic portosystemic shunt in pediatric cystic fibrosis-related liver disease and portal hypertension: prospective long-term results"],"prefix":"10.4274","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8052-539X","authenticated-orcid":false,"given":"Laurens","family":"Hermie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5609-3726","authenticated-orcid":false,"given":"Stephanie Van","family":"Biervliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0736-2034","authenticated-orcid":false,"given":"Anne","family":"Hoorens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4002-8262","authenticated-orcid":false,"given":"Lien Van","family":"Cauwenberghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddy","family":"Robberecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5814-2798","authenticated-orcid":false,"given":"Luc","family":"Defreyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2811","published-online":{"date-parts":[[2024,1,1]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373(9678):1891-1904. [CrossRef]","DOI":"10.1016\/S0140-6736(09)60327-5"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Flass T, Narkewicz MR. Cirrhosis and other liver disease in cystic fibrosis. J Cyst Fibros. 2013;12(2):116-124. [CrossRef]","DOI":"10.1016\/j.jcf.2012.11.010"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Bo\u00eblle PY, Debray D, Guillot L, Clement A, Corvol H; French CF Modifier Gene Study Investigators. Cystic fibrosis liver disease: outcomes and risk factors in a large cohort of French patients. Hepatology. 2019;69(4):1648-1656. [CrossRef]","DOI":"10.1002\/hep.30148"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Debray D, Lykavieris P, Gauthier F, et al. Outcome of cystic fibrosis-associated liver cirrhosis: management of portal hypertension. J Hepatol. 1999;31(1):77-83. [CrossRef]","DOI":"10.1016\/S0168-8278(99)80166-4"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Leung DH, Narkewicz MR. Cystic Fibrosis-related cirrhosis. J Cyst Fibros. 2017;16 (Suppl 2):S50-S61. [CrossRef]","DOI":"10.1016\/j.jcf.2017.07.002"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Debray D, Kelly D, Houwen R, Strandvik B, Colombo C. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J Cyst Fibros. 2011;10 (Suppl 2):S29-S36. [CrossRef]","DOI":"10.1016\/S1569-1993(11)60006-4"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Rowland M, Gallagher C, Gallagher CG, et al. Outcome in patients with cystic fibrosis liver disease. J Cyst Fibros. 2015;14(1):120-126. [CrossRef]","DOI":"10.1016\/j.jcf.2014.05.013"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Witters P, Libbrecht L, Roskams T, et al. Liver disease in cystic fibrosis presents as non-cirrhotic portal hypertension. J Cyst Fibros. 2017;16(5):e11-e13. [CrossRef]","DOI":"10.1016\/j.jcf.2017.03.006"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Wu H, Vu M, Dhingra S, et al. Obliterative portal venopathy without cirrhosis is prevalent in pediatric cystic fibrosis liver disease with portal hypertension. Clin Gastroenterol Hepatol. 2019;17(10):2134-2136. [CrossRef]","DOI":"10.1016\/j.cgh.2018.10.046"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Hillaire S, Cazals-Hatem D, Bruno O, et al. Liver transplantation in adult cystic fibrosis: clinical, imaging, and pathological evidence of obliterative portal venopathy. Liver Transpl. 2017;23(10):1342-1347. [CrossRef]","DOI":"10.1002\/lt.24842"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Cipolli M, Fethney J, Waters D, et al. Occurrence, outcomes and predictors of portal hypertension in cystic fibrosis: a longitudinal prospective birth cohort study. J Cyst Fibros. 2020;19(3):455-459. [CrossRef]","DOI":"10.1016\/j.jcf.2019.09.016"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Dana J, Debray D, Beaufr\u00e8re A, et al. Cystic fibrosis-related liver disease: clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies. J Hepatol. 2022;76(2):420-434. [CrossRef]","DOI":"10.1016\/j.jhep.2021.09.042"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Da BL, Surana P, Kapuria D, et al. Portal pressure in noncirrhotic portal hypertension: to measure or not to measure. Hepatology. 2019;70(6):2228-2230. [CrossRef]","DOI":"10.1002\/hep.30862"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Siegel MJ, Freeman AJ, Ye W, et al. Heterogeneous liver on research ultrasound identifies children with cystic fibrosis at high risk of advanced liver disease: interim results of a prospective observational case-controlled study. J Pediatr. 2020;219:62-69. [CrossRef]","DOI":"10.1016\/j.jpeds.2019.12.033"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Williams SG, Evanson JE, Barrett N, Hodson ME, Boultbee JE, Westaby D. An ultrasound scoring system for the diagnosis of liver disease in cystic fibrosis. J Hepatol. 1995;22(5):513-521. [CrossRef]","DOI":"10.1016\/0168-8278(95)80444-7"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Etzion O, Takyar V, Novack V, et al. Spleen and liver volumetrics as surrogate markers of hepatic venous pressure gradient in patients with noncirrhotic portal hypertension. Hepatol Commun. 2018;2(8):919-928. [CrossRef]","DOI":"10.1002\/hep4.1198"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Sutton H, Dhawan A, Grammatikopoulos T. Non-invasive markers of portal hypertension: appraisal of adult experience and potential utilisation in children. J Pediatr Gastroenterol Nutr. 2018;66(4):559-569. [CrossRef]","DOI":"10.1097\/MPG.0000000000001882"},{"key":"ref17","unstructured":"18. Leung DH, Ye W, Schwarzenberg SJ, et al. Long-term follow-up and liver outcomes in children with cystic fibrosis and nodular liver on ultrasound in a multi-center study. J Cyst Fibros. 2022:S1569-1993(22)00635-X. [CrossRef]"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Palaniappan SK, Than NN, Thein AW, Moe S, van Mourik I. Interventions for preventing and managing advanced liver disease in cystic fibrosis. Cochrane Database Syst Rev. 2017;8(8):CD012056. [CrossRef]","DOI":"10.1002\/14651858.CD012056.pub2"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Freeman AJ, Sellers ZM, Mazariegos G, et al. A multidisciplinary approach to pretransplant and posttransplant management of cystic fibrosis-associated liver disease. Liver Transpl. 2019;25(4):640-657. [CrossRef]","DOI":"10.1002\/lt.25421"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Debray D, Narkewicz MR, Bodewes FAJA, et al. Cystic fibrosis-related liver disease: research challenges and future perspectives. J Pediatr Gastroenterol Nutr. 2017;65(4):443-448. [CrossRef]","DOI":"10.1097\/MPG.0000000000001676"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Shneider BL, de Ville de Goyet J, Leung DH, et al. Primary prophylaxis of variceal bleeding in children and the role of MesoRex bypass: summary of the Baveno VI Pediatric Satellite Symposium. Hepatology. 2016;63(4):1368-1380. [CrossRef]","DOI":"10.1002\/hep.28153"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Jeanniard-Malet O, Duch\u00e9 M, Fabre A. Survey on clinical practice of primary prophylaxis in portal hypertension in children. J Pediatr Gastroenterol Nutr. 2017;64(4):524-527. [CrossRef]","DOI":"10.1097\/MPG.0000000000001453"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. Tripathi D, Stanley AJ, Hayes PC, et al. Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension. Gut. 2020;69(7):1173-1192. [CrossRef]","DOI":"10.1136\/gutjnl-2019-320221"},{"key":"ref24","unstructured":"25. Pozler O, Krajina A, Vanicek H, et al. Transjugular intrahepatic portosystemic shunt in five children with cystic fibrosis: long-term results. Hepatogastroenterology. 2003;50(52):1111-1114. [CrossRef]"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26. Johansen LC, McKiernan PJ, Sharif K, McGuirk SP. Transjugular intrahepatic portosystemic shunt insertion for the management of portal hypertension in children. J Pediatr Gastroenterol Nutr. 2018;67(2):173-179. [CrossRef]","DOI":"10.1097\/MPG.0000000000002006"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27. Bertino F, Hawkins CM, Shivaram G, et al. Technical feasibility and clinical effectiveness of transjugular intrahepatic portosystemic shunt creation in pediatric and adolescent patients. J Vasc Interv Radiol. 2019;30(2):178-186. [CrossRef]","DOI":"10.1016\/j.jvir.2018.10.003"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28. Hermie L, Dhondt E, Vanlangenhove P, Hoste E, Geerts A, Defreyne L. Model for end-stage liver disease score and hemodynamic instability as a predictor of poor outcome in early transjugular intrahepatic portosystemic shunt treatment for acute variceal hemorrhage. Eur J Gastroenterol Hepatol. 2018;30(12):1441-1446. [CrossRef]","DOI":"10.1097\/MEG.0000000000001222"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29. Megremis SD, Vlachonikolis IG, Tsilimigaki AM. Spleen length in childhood with US: normal values based on age, sex, and somatometric parameters. Radiology. 2004;231(1):129-134. [CrossRef]","DOI":"10.1148\/radiol.2311020963"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30. Roelants M, Hauspie R, Hoppenbrouwers K. References for growth and pubertal development from birth to 21 years in Flanders, Belgium. Ann Hum Biol. 2009;36(6):680-694. [CrossRef]","DOI":"10.3109\/03014460903049074"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31. Dariushnia SR, Haskal ZJ, Midia M, et al. Quality improvement guidelines for transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol. 2016;27(1):1-7. [CrossRef]","DOI":"10.1016\/j.jvir.2015.09.018"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32. Witters P, Libbrecht L, Roskams T, et al. Noncirrhotic presinusoidal portal hypertension is common in cystic fibrosis-associated liver disease. Hepatology. 2011;53(3):1064-1065. [CrossRef]","DOI":"10.1002\/hep.24183"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24(2):289-293. [CrossRef]","DOI":"10.1002\/hep.510240201"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"34. Di Giorgio A, Nicastro E, Agazzi R, Colusso M, D'Antiga L. Long-term outcome of transjugular intrahepatic portosystemic shunt in children with portal hypertension. J Pediatr Gastroenterol Nutr. 2020;70(5):615-622. [CrossRef]","DOI":"10.1097\/MPG.0000000000002597"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"35. Perarnau JM, Le Gouge A, Nicolas C, et al. Covered vs. uncovered stents for transjugular intrahepatic portosystemic shunt: a randomized controlled trial. J Hepatol. 2014;60(5):962-968. [CrossRef]","DOI":"10.1016\/j.jhep.2014.01.015"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"36. Bosch J, Groszmann RJ, Shah VH. Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments. J Hepatol. 2015;62(Suppl 1):S121-S130. [CrossRef]","DOI":"10.1016\/j.jhep.2015.01.003"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"37. Verbeeck S, Mekhali D, Cassiman D, Maleux G, Witters P. Long-term outcome of transjugular intrahepatic portosystemic shunt for portal hypertension in autosomal recessive polycystic kidney disease. Dig Liver Dis. 2018;50(7):707-712. [CrossRef]","DOI":"10.1016\/j.dld.2018.03.009"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"38. Liu J, Ma J, Yang C, et al. Impact of TIPS on splenic volume and thrombocytopenia. AJR Am J Roentgenol. 2021;216(3):698-703. [CrossRef]","DOI":"10.2214\/AJR.20.22958"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"39. Liu J, Ma J, Yang C, et al. Impact of TIPS on splenic volume and thrombocytopenia. AJR Am J Roentgenol. 2021;216(3):698-703. [CrossRef]","DOI":"10.2214\/AJR.20.22958"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"40. Lemoine C, Lokar J, McColley SA, Alonso EM, Superina R. Cystic fibrosis and portal hypertension: distal splenorenal shunt can prevent the need for future liver transplant. J Pediatr Surg. 2019;54(5):1076-1082. [CrossRef]","DOI":"10.1016\/j.jpedsurg.2019.01.035"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"41. Koh C, Sakiani S, Surana P, et al. Adult-onset cystic fibrosis liver disease: diagnosis and characterization of an underappreciated entity. Hepatology. 2017;66(2):591-601. [CrossRef]","DOI":"10.1002\/hep.29217"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"42. Ye W, Narkewicz MR, Leung DH, et al. Variceal hemorrhage and adverse liver outcomes in pa-tients with cystic fibrosis cirrhosis. J Pediatr Gastroenterol Nutr. 2018;66(1):122-127. [CrossRef]","DOI":"10.1097\/MPG.0000000000001728"}],"container-title":["Diagnostic and Interventional Radiology"],"original-title":[],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T08:18:32Z","timestamp":1738311512000},"score":1,"resource":{"primary":{"URL":"https:\/\/dirjournal.org\/articles\/doi\/dir.2022.221818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,1]]},"published-print":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.4274\/dir.2022.221818","relation":{},"ISSN":["1305-3825","1305-3612"],"issn-type":[{"value":"1305-3825","type":"print"},{"value":"1305-3612","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,1]]}}}